Your session is about to expire
← Back to Search
Eplerenone for Primary Aldosteronism
Study Summary
This trial will study if a medication that blocks aldosterone can reduce heart & kidney disease risk for those with too much of the hormone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 4 trial • 1012 Patients • NCT01176968Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of heart issues, including heart attack, heart surgery, weak heart muscle, or heart transplant.I am allergic or cannot take eplerenone or spironolactone.I am scheduled for adrenal gland surgery within the next 6 months.I am scheduled for a heart vessel examination or treatment within the next 6 months.I weigh less than 500 pounds and can fit into a PET/CT scanner.I've had a heart PET scan and an echocardiogram recently.I am taking medication for high blood pressure.I am between 18 and 85 years old.Your kidney function (eGFR) is very low or your potassium levels are very high based on recent lab tests.I have primary aldosteronism and haven't been treated with mineralocorticoid receptor antagonists.Cohort B: PET scan shows 10% or more of the heart has reduced blood flow.
- Group 1: Eplerenone Treatment
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned Eplerenone Treatment?
"As this drug is already approved, our team at Power have rated the safety of Eplerenone Treatment to be a 3 on a scale from 1-3."
Are the age restrictions for this research study accommodating those over 50?
"Based on the criteria for enrollment, participants must be at least 18 years old and no older than 85."
What medical condition is Eplerenone Treatment typically prescribed to treat?
"Patients with congestive heart failure, hypertensive disease, and hypesthesia can be managed through Eplerenone Treatment if their left ventricular ejection fraction is below 40%."
Are recruitment efforts underway for this clinical trial?
"Yes, this research is actively recruiting. The initial posting was on December 15th 2022 and the information has been recently refreshed as of February 24th 2023."
What qualifications do prospective participants need to meet in order to be eligible for this trial?
"This research trial is open to persons aged between 18 and 85 with hypertension, who have the potential of being 40 participants."
What is the current participation rate of this clinical trial?
"Affirmative, according to the information available on clinicaltrials.gov this trial is now recruiting participants. This investigation was uploaded online on December 15th 2022 and its most recent update took place on February 24th 2023; thus far 40 individuals have been sought from one location."
Share this study with friends
Copy Link
Messenger